SCHEMBL5073736

SCHEMBL5073736

O=C(O)OCC(O)C(O)C(O)C(O)CO.[AlH3].[NaH]

nearest known ligand 0.48

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.48
LMNA P02545 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
USP2 O75604 1/20 0.45
SLCO1B1 Q9Y6L6 1/20 0.45
TDP1 Q9NUW8 1/20 0.44
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 1/20 0.33
PRKCA P17252 1/20 0.31
OR51E2 Q9H255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1403805 0.96 PDE4A (0.52) PDE4ALMNAL3MBTL1USP2SLCO1B1
SCHEMBL7170688 0.96 PDE4A (0.52) PDE4ALMNAL3MBTL1USP2SLCO1B1
SCHEMBL3810811 0.96 PDE4A (0.52) PDE4ALMNAL3MBTL1USP2SLCO1B1
SCHEMBL1892966 0.94 PDE4A (0.50) PDE4ALMNAL3MBTL1USP2SLCO1B1
SCHEMBL5139535 0.91 PDE4A (0.46) PDE4ALMNAL3MBTL1USP2SLCO1B1
SCHEMBL2123186 0.89 PDE4A (0.45) PDE4ALMNAL3MBTL1USP2SLCO1B1
SCHEMBL1032576 0.87 ALDH1A1 (0.40) PDE4ALMNAL3MBTL1USP2SLCO1B1
SCHEMBL16894036 0.82 ALDH1A1 (0.42) PDE4ALMNAL3MBTL1USP2SLCO1B1
SCHEMBL23414176 0.80 PDE4A (0.45) PDE4ALMNAL3MBTL1USP2SLCO1B1
SCHEMBL23414148 0.80 PDE4A (0.45) PDE4ALMNAL3MBTL1USP2SLCO1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6645535-B2 Gastrointestinal disorders WM. WRIGLEY JR. COMPANY 2003-11-11 US claimed
WO-2002051259-A1 COATED CHEWING GUM PRODUCTS CONTAINING VARIOUS ANTACIDS WM. WRIGLEY JR. COMPANY (US) 2002-07-04 WO claimed
US-20010021403-A1 Coated chewing gum products containing various antacids WM. WRIGLEY JR. COMPANY 2001-09-13 US claimed
US-20080153880-A1 PAN-ALPHA-2 RECEPTOR AGONIST AND ACID REDUCER COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS ALLERGAN, INC. 2008-06-26 US disclosed
US-20080153881-A1 ALPHA-2B RECEPTOR AGONIST AND ACID REDUCER COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS ALLERGAN, INC. 2008-06-26 US disclosed
US-20070239104-A1 Anti acid G/tube pad FEERRAR ANGELA C 2007-10-11 US disclosed
US-6645535-B2 Gastrointestinal disorders WM. WRIGLEY JR. COMPANY 2003-11-11 US disclosed
WO-2002051259-A1 COATED CHEWING GUM PRODUCTS CONTAINING VARIOUS ANTACIDS WM. WRIGLEY JR. COMPANY (US) 2002-07-04 WO disclosed
US-20010021403-A1 Coated chewing gum products containing various antacids WM. WRIGLEY JR. COMPANY 2001-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153880-A1 PAN-ALPHA-2 RECEPTOR AGONIST AND ACID REDUCER COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS MLNR, GIPR, FFAR2 PDE4A 385/4885LMNA 4032/4885L3MBTL1 4752/4885
US-20080153881-A1 ALPHA-2B RECEPTOR AGONIST AND ACID REDUCER COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS ADRA2B, GPBAR1, MLNR PDE4A 260/4885LMNA 3459/4885L3MBTL1 4742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.